Want to see ASND full AI Analyst Report?
Total Valuation
Ascendis Pharma has a market cap or net worth of $15.89B. The enterprise value is $17.81K.
Market Cap$15.89B
Enterprise Value$17.81K
Share Statistics
Ascendis Pharma has 62,376,846 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding62,376,846
Owned by Insiders0.01%
Owned by Institutions62.90%
Financial Efficiency
Ascendis Pharma’s return on equity (ROE) is 1.35 and return on invested capital (ROIC) is -18.19%.
Return on Equity (ROE)1.35
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-18.19%
Return on Capital Employed (ROCE)-0.56
Revenue Per Employee581.76K
Profits Per Employee-184.22K
Employee Count1,189
Asset Turnover0.53
Inventory Turnover0.34
Valuation Ratios
The current PE Ratio of Ascendis Pharma is 17.9. Ascendis Pharma’s PEG ratio is 1.13.
PE Ratio17.9
PS Ratio15.90
PB Ratio-67.58
Price to Fair Value-67.58
Price to FCF252.17
Price to Operating Cash Flow39.71
PEG Ratio1.13
Income Statement
In the last 12 months, Ascendis Pharma had revenue of 691.71M and earned -219.03M in profits. Earnings per share was -3.62.
Revenue691.71M
Gross Profit588.53M
Operating Income-130.89M
Pretax Income-204.26M
Net Income-219.03M
EBITDA-109.80M
Earnings Per Share (EPS)-3.62
Cash Flow
In the last 12 months, operating cash flow was 351.32M and capital expenditures -14.43M, giving a free cash flow of 336.90M billion.
Operating Cash Flow351.32M
Free Cash Flow336.90M
Free Cash Flow per Share5.40
Dividends & Yields
Ascendis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change30.36%
50-Day Moving Average252.20
200-Day Moving Average229.70
Relative Strength Index (RSI)51.35
Average Volume (3m)764.15K
Important Dates
Ascendis Pharma upcoming earnings date is Nov 11, 2026, After Close (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Ascendis Pharma as a current ratio of 1.04, with Debt / Equity ratio of 31.33%
Current Ratio1.04
Quick Ratio0.76
Debt to Market Cap0.08
Net Debt to EBITDA-2.33
Interest Coverage Ratio-1.69
Taxes
In the past 12 months, Ascendis Pharma has paid 14.78M in taxes.
Income Tax14.78M
Effective Tax Rate-0.07
Enterprise Valuation
Ascendis Pharma EV to EBITDA ratio is -102.51, with an EV/FCF ratio of 258.03.
EV to Sales16.27
EV to EBITDA-102.51
EV to Free Cash Flow258.03
EV to Operating Cash Flow217.41
Balance Sheet
Ascendis Pharma has $811.92M in cash and marketable securities with $449.89M in debt, giving a net cash position of $362.04M billion.
Cash & Marketable Securities$811.92M
Total Debt$449.89M
Net Cash$362.04M
Net Cash Per Share$5.80
Tangible Book Value Per Share-$2.75
Margins
Gross margin is 90.19%, with operating margin of -18.92%, and net profit margin of -31.67%.
Gross Margin90.19%
Operating Margin-18.92%
Pretax Margin-29.53%
Net Profit Margin-31.67%
EBITDA Margin-15.87%
EBIT Margin-18.33%
Analyst Forecast
The average price target for Ascendis Pharma is $311.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$311.27
Price Target Upside22.61% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast128.41%
EPS Growth Forecast―